<DOC>
	<DOCNO>NCT00295165</DOCNO>
	<brief_summary>The purpose study evaluate Leukine induce clinical response remission patient Crohn 's disease .</brief_summary>
	<brief_title>Efficacy ( Induction Response/Remission ) Safety Study Patients With Moderate Severe Crohn 's Disease</brief_title>
	<detailed_description>On 29 May 2009 , Bayer begin transition sponsorship trial Genzyme . NOTE : This study originally post sponsor Berlex , Inc. Berlex , Inc. rename Bayer HealthCare , Inc .</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>1 . Written inform consent 2 . Male female , age &gt; /= 18 year 3 . Confirmed diagnosis Crohn 's disease ( endoscopic radiological evaluation ) least 4 month prior receive first dose study drug 4 . Moderately severely active Crohn 's disease time screen ( i.e. , CDAI great equal 220 less equal 475 point ) 5 . If treatment Crohn 's disease , medication must stable least 4 week prior receive first dose study drug . The following therapy allow : Oral therapy salicylate ( mesalamine , sulfasalazine , olsalazine , balsalazide ) Crohn 's disease Antibiotics probiotic Crohn 's disease Topical rectal therapy mesalamine 6 . Females childbearing potential : Negative pregnancy test within 72 hour prior receive first dose study drug 7 . Sexuallyactive male female childbearing potential : Agreement use adequate method contraception throughout study 8 . Ability selfinject study drug availability designee 1 . Pregnancy breastfeed 2 . Colostomy ileostomy 3 . Immediate need gastrointestinal ( GI ) surgery active GI bleeding , peritonitis , intestinal obstruction , intraabdominal perianal abscess require surgical drainage 4 . GI surgery within 6 month prior receive first dose study drug 5 . Symptoms bowel obstruction confirm evidence clinicallysignificant stricture within last 6 month surgically correct 6 . Positive stool test result follow : Bacteria : Salmonella spec . Shigella spec . Campylobacter spec . Bacterial toxin : Clostridium difficile Ova parasites : Amoeba spec . Giardia spec . Cryptosporidium spec . 7 . Any following laboratory abnormality : Serum creatinine &gt; /= 2.0 mg/dL Alkaline phosphatase ( AP ) , aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) , total bilirubin &gt; /= ; 2 x upper limit normal Hemoglobin ( Hgb ) &lt; 8.0 g/dL Absolute neutrophil count ( ANC ) &lt; /= 1,000 cells/µL &gt; cell 20,000/µL 8 . Planned inpatient hospitalization study 9 . Presence history cancer type ( except treat basal cell carcinoma ) definite dysplasia colon within last 5 year 10 . Use following medication specify period time prior receive first dose study drug : At time : Recombinant human GM CSF ( sargramostim molgramostim ) Granulocyte colonystimulating factor ( G CSF ; filgrastim pegfilgrastim ) Natalizumab 8 week : 5 halflives ( whichever longer ) Licensed/registered and/or experimental antitumor necrosis factor ( TNF ) therapy infliximab adalimumab 4 week : 6mercaptopurine Azathioprine Cyclophosphamide Methotrexate Mycophenolate mofetil Tacrolimus Cyclosporine Thalidomide Glucocorticoids , include budesonide prednisone , local glucocorticoid therapy Crohn 's disease Any immunosuppressive drug 11 . Use investigational drug within 4 week 5 halflives ( whichever longer ) prior receive first dose study drug 12 . Use nutritional therapy ( parenteral nutrition enteral nutrition elemental semielemental diet ) within 4 week prior receive first dose study drug . If physician judge nutritional supplementation need , enteral nutritional supplement allow patient receive stable regimen least 4 week prior receive first dose study drug intend continue 8 week treatment period . 13 . History allergy yeast product sargramostim excipient study drug formulation 14 . Active drug alcohol abuse 15 . Clinically important comorbid condition unrelated Crohn 's disease determine investigator 16 . Previous randomization study , study sponsor 's sargramostim development program</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>